Skip to main content
. 2021 May 4;4:100102. doi: 10.1016/j.jtauto.2021.100102

Figure-2.

Figure-2

STAT-1 phosphorylation assay: Functional STAT-1 phosphorylation (pSTAT-1) flow assay using stimulation with different concentrations of IFNγ. Healthy control cells in the presence of 10% healthy control plasma shows maximal STAT-1 phosphorylation at 100 U/mL (not shown). Patient plasma (7/21/14) prior to rituximab blocks STAT-1 phosphorylation in healthy control cells at the highest dose of 50,000 U/mL IFNγ. In 8/22/18 after treatment with rituximab, partial STAT-1 phosphorylation is present at 40,000 U/mL IFNγ and is fully restored at 50,000 U/mL IFNγ. Repeat assay on 8/11/20 after completing one-year of bortezomib combined with rituximab, STAT-1 phosphorylation is restored, but only at IFNγ concentrations of 30,000 U/mL and above, indicating significant and continued pSTAT1 blockade compared to healthy control plasma.